Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer (Q33410022)

26 July 2017

title

Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer (English)

1 reference

26 July 2017

main subject

phase I clinical trial

0 references

Prasanth Ganesan

1

0 references

Sarina Piha-Paul

object named as

Sarina Piha-Paul

Apostolia Maria Tsimberidou

2

0 references

object named as

Apostolia M Tsimberidou

10

0 references

Aung Naing

3

object named as

Aung Naing

1 reference

26 July 2017

6

Filip Janku

1 reference

26 July 2017

4

Gerald Falchook

1 reference

26 July 2017

Jennifer Wheler

5

1 reference

26 July 2017

Ralph Zinner

7

1 reference

26 July 2017

Shell Laday

8

1 reference

26 July 2017

Merrill Kies

9

1 reference

26 July 2017

language of work or name

1 reference

28 August 2013

1 reference

Investigational New Drugs

26 July 2017

published in

1 reference

26 July 2017

volume

31

1 reference

26 July 2017

issue

6

1 reference

26 July 2017

page(s)

1505-1513

1 reference

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S10637-013-0013-1

Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-013-0013-1

Lenalidomide in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-013-0013-1

Temsirolimus: in advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-013-0013-1

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-013-0013-1

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-013-0013-1

Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-013-0013-1

Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-013-0013-1

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-013-0013-1

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-013-0013-1

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-013-0013-1

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-013-0013-1

Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-013-0013-1

Lenalidomide therapy for metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-013-0013-1

Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-013-0013-1

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-013-0013-1

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10637-013-0013-1

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

12 December 2020

Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma

1 reference

12 December 2020

Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies

1 reference

12 December 2020

Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha

1 reference

12 December 2020

Phase II study of lenalidomide in patients with metastatic renal cell carcinoma

1 reference

12 December 2020

10.1007/S10637-013-0013-1

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

1013457063

0 references

1 reference